We are live on ! Find out more
NCM

Nantahala Capital Management Portfolio holdings

AUM $2.72B
1-Year Est. Return 121.58%
This Fund
S&P 500
This Quarter Est. Return
+17.36%
1 Year Est. Return
+121.58%
3 Year Est. Return
+308.64%
5 Year Est. Return
+308.9%
10 Year Est. Return
+2,888.73%
AUM
$1.98B
AUM Growth
+$266M
Cap. Flow
+$123M
Cap. Flow %
6.23%
Top 10 Hldgs %
54.68%
Holding
148
New
19
Increased
38
Reduced
28
Closed
8

Top Buys

Rank Stock Value
1
FULC icon
Fulcrum Therapeutics
FULC
+$35.4M
2
TITN icon
Titan Machinery
TITN
+$24.4M
3
BKSY icon
BlackSky Technology
BKSY
+$19.4M
4
CRMT icon
America's Car Mart
CRMT
+$13.5M
5
PWSC
PowerSchool Holdings, Inc.
PWSC
+$13.2M

Top Sells

Rank Stock Value
1
CASH icon
Pathward Financial
CASH
+$17.8M
2
IMAX icon
IMAX
IMAX
+$10.2M
3
BVS icon
Bioventus
BVS
+$8.54M
4
ESTA icon
Establishment Labs
ESTA
+$6.68M
5
RDNW
RideNow Group
RDNW
+$5.58M

Sector Composition

Rank Sector Weight
1 Healthcare 41.22%
2 Consumer Discretionary 6.49%
3 Communication Services 3.21%
4 Financials 3.01%
5 Industrials 2.66%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AMLX icon
76
Amylyx Pharmaceuticals
AMLX
$2.58B
$4.55M 0.23%
+1,404,564
New +$3.16M
GAIA icon
77
Gaia
GAIA
$33.9M
$4.46M 0.23%
915,029
– –
DHX icon
78
DHI Group
DHX
$160M
$4.31M 0.22%
2,376,606
+310,189
+15% +$590K
NPCE icon
79
Neuropace
NPCE
$504M
$4.24M 0.21%
607,890
-8,933
-1% -$65.3K
ZYXI
80
DELISTED
Zynex
ZYXI
$4M 0.2%
490,000
– –
CNTX icon
81
Context Therapeutics
CNTX
$43.2M
$3.79M 0.19%
1,935,484
– –
EGRX
82
CALL
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$3.73M 0.19%
1,000,000
– –
SLN
83
Silence Therapeutics
SLN
$708M
$3.64M 0.18%
200,000
– –
LXRX icon
84
Lexicon Pharmaceuticals
LXRX
$1.05B
$3.62M 0.18%
2,304,150
– –
BCOV
85
DELISTED
Brightcove, Inc.
BCOV
$3.6M 0.18%
1,664,768
+351,000
+27% +$784K
SCPH
86
DELISTED
scPharmaceuticals
SCPH
$3.42M 0.17%
+750,000
New +$3.63M
GOGO icon
87
Gogo Inc
GOGO
$423M
$3.41M 0.17%
+475,497
New +$3.88M
THTX
88
DELISTED
Theratechnologies
THTX
$3.33M 0.17%
2,682,228
– –
ABEO icon
89
CALL
Abeona Therapeutics
ABEO
$430M
$3.29M 0.17%
520,000
– –
ACHV icon
90
Achieve Life Sciences
ACHV
$693M
$3.1M 0.16%
654,000
– –
DRIO icon
91
DarioHealth
DRIO
$76.3M
$2.8M 0.14%
125,166
+5,600
+5% +$114K
MIST icon
92
Milestone Pharmaceuticals
MIST
$156M
$2.66M 0.13%
1,750,000
– –
AYTU icon
93
AYTU BioPharma
AYTU
$25.5M
$2.55M 0.13%
1,086,812
– –
SRZN icon
94
Surrozen
SRZN
$299M
$2.24M 0.11%
187,206
– –
MAX icon
95
MediaAlpha
MAX
$804M
$2.24M 0.11%
123,564
– –
FOSL icon
96
Fossil Group
FOSL
$308M
$2.23M 0.11%
1,905,278
– –
XBI icon
97
State Street SPDR S&P Biotech ETF
XBI
$10.3B
$2.14M 0.11%
21,646
-723
-3% -$71K
NVNO
98
enVVeno Medical
NVNO
$7.17M
$2.01M 0.1%
17,055
+3,402
+25% +$625K
SRL icon
99
Scully Royalty
SRL
$89.5M
$1.91M 0.1%
239,197
– –
TELA icon
100
CALL
TELA Bio
TELA
$38.1M
$1.9M 0.1%
+750,000
New +$2.67M
2 3
4
5 6

Similar funds

TAM
Timucuan Asset Management Jacksonville, Florida $2.72B AUM 4.95% 1-Year Est. Return
XL
XN LP New York $2.72B AUM 46.67% 1-Year Est. Return
NB
Nicolet Bankshares Green Bay, Wisconsin $2.71B AUM 17.55% 1-Year Est. Return
PA
Profund Advisors Bethesda, Maryland $2.72B AUM 47.27% 1-Year Est. Return
BCM
Bowie Capital Management Richardson, Texas $2.71B AUM 5.42% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.57% 1-Year Est. Return
HCM
Hollencrest Capital Management Newport Beach, California $2.7B AUM 23.62% 1-Year Est. Return
GC
Giverny Capital Montreal, Quebec, Canada $2.73B AUM 14.09% 1-Year Est. Return

Nantahala Capital Management's Q3 2024 Portfolio in Review

As of Q3 2024, Nantahala Capital Management held 148 positions worth $1.98B, up 16% from $1.71B the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Nantahala Capital Management deployed $123M of net new capital in Q3 2024, opening 19 new positions and adding to 38 existing holdings. Its largest new stake was Fulcrum Therapeutics: 4,777,912 shares worth $17.1M.

By sector, the portfolio is most concentrated in Healthcare at 41% of assets, up from 40% a quarter earlier, followed by Consumer Discretionary and Communication Services.

On the sell side, the largest reduction was Pathward Financial, an estimated $17.8M trimmed.

  • Nantahala Capital Management's largest Q3 2024 buy was Fulcrum Therapeutics: 4,777,912 shares worth $17.1M.
  • Nantahala Capital Management added most to America's Car Mart in Q3 2024, an estimated $13.5M increase.
  • Nantahala Capital Management's biggest Q3 2024 reduction was Pathward Financial, cutting an estimated $17.8M.
  • Nantahala Capital Management fully exited Avadel Pharmaceuticals in Q3 2024, selling an estimated $4.92M.
  • Nantahala Capital Management's ten largest holdings make up 55% of its $1.98B portfolio in Q3 2024.
  • Nantahala Capital Management opened 19 new positions and closed 8 in Q3 2024.
  • Nantahala Capital Management's portfolio value rose 16% quarter-over-quarter to $1.98B.

Based on Nantahala Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.